Assessment of the Prognostic Value of Two Common Variants of BRCA1 and BRCA2 Genes in Ovarian Cancer Patients Treated with Cisplatin and Paclitaxel: A Gynecologic Oncology Group Study

Assessment of the Prognostic Value of Two Common Variants of BRCA1 and BRCA2 Genes in Ovarian Cancer Patients Treated with Cisplatin and Paclitaxel: A Gynecologic Oncology Group Study

Purpose: BRCA1/BRCA2 germline mutations appear to enhance the platinum-sensitivity, but little is known about the prognostic relevance of polymorphisms in BRCA1/BRCA2 in epithelial ovarian cancer (EOC). This study evaluated whether common variants of BRCA1/BRCA2 are associated with progression-free...

Full description

Bibliographic Details
Main Authors: Chunqiao eTian, Kathleen M Darcy, Christine B Ambrosone, Thomas C Krivak
Format: Article
Language:English
Published: Frontiers Media S.A. 2013-08-01
Series:Frontiers in Oncology
Subjects:
chemotherapy
prognosis
ovarian cancer
polymorphism
BRCA
Online Access:http://journal.frontiersin.org/Journal/10.3389/fonc.2013.00206/full

Internet

http://journal.frontiersin.org/Journal/10.3389/fonc.2013.00206/full

Similar Items